Market Overview

The Medicines Co., Bristol-Myers Begin Alliance for Recothrom

Related MDCO
Chardan Rates Regeneron A Sell, Advises Caution
20 Stocks Which Rallied Three Days On Increasing Volume
Related BMY
Brean Likes Nektar Therapeutics' Upcoming Launches; Assumes Coverage At Buy
Technical Alert: Bristol-Myers Squibb Makes New Low For The Move
What Will Gilead Try Buying Next? Polls Offer Some 'Incyte' (Investor's Business Daily)

The Medicines Company (NASDAQ: MDCO) announced today that the global license and two-year collaboration for Recothrom(R), a recombinant thrombin approved by the U.S. Food and Drug Administration for use as a topical hemostat to control non-arterial bleeding during surgical procedures, established with Bristol-Myers Squibb Company (NYSE: BMY) has become effective. The agreement was first announced in December 2012. The companies have satisfied all required regulatory and closing conditions.

Posted-In: News


Related Articles (MDCO + BMY)

View Comments and Join the Discussion!